Kamada Remains Focused on Lung Treatment: CEO Tsur

The transcript discusses the failure of a trial for an inhaled version of A1 treatment, which affects hereditary emphysema. The company plans to meet with the European Agency for conditional approval due to unmet needs. Despite investor concerns about the inhaled treatment's potential revenue loss, the company aims to create value from existing data and continue clinical development. Kamada has a strong business base with products in 15 countries and strategic partnerships. The intravenous version of the treatment is a growing market, and the company has a promising pipeline, including treatments for rabies, cystic fibrosis, and diabetes. Financially, Kamada is stable with sufficient cash flow to support development.

What is Kamada's next step after the failure of the inhaled A1 treatment trial?

• Shift to a different treatment entirely

• Focus solely on the US market

• Discontinue all A1 treatment trials

• Seek conditional approval from the European Agency

How does Kamada plan to create value despite the trial setback?

• By leveraging existing data and continuing clinical development

• By exploring new markets

• By selling the company

• By cutting costs significantly

What is the significance of Kamada's intravenous product?

• It is a declining market

• It is a stable and growing business

• It is only available in the US

• It has no strategic partnerships

Which of the following is NOT a focus area for Kamada's orphan treatments?

• Type 2 Diabetes

• GVHD

• Cystic Fibrosis

• Rabies

Does Kamada have enough cash to reach profitability?

• No, they are planning to sell assets

• Yes, but only if they cut costs

• No, they need additional funding

• Yes, with strong revenues and cash flow